Basagine Dosage/Direction for Use

Dosing: Insulin Glargine (Basagine) is a recombinant human insulin analogue for once daily subcutaneous administration with potency that is approximately the same as the potency of human insulin.
Insulin Glargine (Basagine) exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing.
Insulin Glargine (Basagine) may be administered at any time during the day. Insulin Glargine (Basagine) should be administered subcutaneously once a day at the same time every day. The dose of Insulin glargine must be individualized based on clinical response. Blood glucose monitoring is essential in all patients receiving insulin therapy.
Patients adjusting the amount or timing of dosing with Insulin Glargine (Basagine), should only do so under medical supervision with appropriate glucose monitoring.
In patients with type 1 diabetes, Insulin Glargine (Basagine) must be used in regimens with short-acting insulin.
The intended duration of activity of Insulin Glargine is dependent on injection into subcutaneous tissue. Insulin Glargine should not be administered intravenously or via an insulin pump. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.
As with all insulins, injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next to reduce the risk of lipodystrophy.
Initiation therapy: The recommended starting dose of Insulin Glargine (Basagine) in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, pre-meal insulin should be used to satisfy the remainder of the daily insulin requirements.
The recommended starting dose of Insulin Glargine (Basagine) in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient's needs.
The dose of Insulin Glargine should be adjusted according to blood glucose measurements. The dosage of Insulin Glargine should be individualized under the supervision of healthcare provider in accordance with the needs of the patient.
Converting to Insulin Glargine from other insulin therapies: If changing from a treatment regimen with an intermediate-or long-acting insulin to a regimen with Insulin Glargine, the amount and timing of shorter-acting insulins and doses of any oral antidiabetic drugs may need to be adjusted.
If transferring patients from once-daily NPH insulin to once-daily Insulin Glargine, the recommended initial Insulin Glargine dose is the same as the dose of Insulin Glargine that is being discontinued.
If transferring patients from twice-daily NPH insulin to once-daily Insulin Glargine, the recommended initial Insulin Glargine dose is 80% of the total NPH dose that is being discontinued. This dose reduction will lower the likelihood of hypoglycaemia.